



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	Jurkat tat+ Cells
Catalog Number:	1399
Lot Number:	100306
Release Category:	D
Provided:	3.3 x 10 ⁶ cells/mL. Viability is 86%.
Cell Type:	Human T-lymphocytic cell line.
Propagation Medium:	RPMI 1640, 90%; fetal bovine serum, 10%; G418, 800 µg/ml.
Freeze Medium:	Fetal bovine serum, 90%; DMSO, 10%.
Growth Characteristics:	Maintain cells at approximately 5 x 10 ⁵ cells/ml. Doubling time is 25 hours. Passage twice weekly. Jurkat- <i>tat</i> cells grow in suspension both singly and as clumps.
Morphology:	Lymphocytic; very similar to parent cell line.
Sterility:	Negative for mycoplasma, bacteria and fungi.
Special Characteristics:	A BK virus expression vector containing HIV-1 <i>tat</i> cDNA and a neomycin resistance selection marker was used to transfect Jurkat cells. The resultant cell line stably expresses HIV-1 Tat. It is unclear whether Tat is secreted into the culture medium. These cells are CD4 ⁺ and are easily infected with HIV-1.
Recommended Storage:	Liquid nitrogen.
Contributor:	Drs. Antonella Caputo, William Haseltine, and Joseph Sodroski.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References: Caputo A, Sodroski JG, Haseltine WA. Constitutive expression of HIV-1 *tat* protein in human Jurkat T cells using a BK virus vector. *J Acquired Immune Defic Syndr* **3**:372-379, 1990.

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Jurkat tat+ Cells from Drs. Antonella Caputo, William Haseltine, and Joseph Sodroski." Also include the reference cited above in any publications.

This and other stable cell lines expressing tat III is described in US Patent #4,981,790. Requests from commercial organizations must be directed to both Dr. Joseph Sodroski, Division of Human Retrovirology, JFB824, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA, 02115, and the Director, Office of Technology Transfer, Dana-Farber Cancer Institute, 44 Binney Street, Suite L660, Boston, MA 02115.

Last Updated March 19, 2019

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.